| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.
|
2012
|
1.36
|
|
2
|
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.
|
2012
|
1.34
|
|
3
|
Integrin signaling in cancer cell survival and chemoresistance.
|
2012
|
1.26
|
|
4
|
Neurotoxicity caused by the treatment with platinum analogues.
|
2011
|
1.12
|
|
5
|
Current chemotherapeutic management of patients with gestational trophoblastic neoplasia.
|
2011
|
1.06
|
|
6
|
Imatinib: a breakthrough of targeted therapy in cancer.
|
2014
|
1.04
|
|
7
|
Chemotherapy and dietary phytochemical agents.
|
2012
|
1.03
|
|
8
|
Triple-negative breast cancer: adjuvant therapeutic options.
|
2011
|
1.03
|
|
9
|
β-Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells.
|
2012
|
0.99
|
|
10
|
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis.
|
2012
|
0.95
|
|
11
|
Nedaplatin: a radiosensitizing agent for patients with cervical cancer.
|
2010
|
0.95
|
|
12
|
Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.
|
2012
|
0.92
|
|
13
|
High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases.
|
2013
|
0.92
|
|
14
|
Chemotherapy-induced oesophageal stricture in a child with osteosarcoma: a case report.
|
2010
|
0.92
|
|
15
|
The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients.
|
2014
|
0.91
|
|
16
|
Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.
|
2012
|
0.91
|
|
17
|
Advances in Targeting HER3 as an Anticancer Therapy.
|
2012
|
0.90
|
|
18
|
Induction chemotherapy in technically unresectable locally advanced carcinoma of maxillary sinus.
|
2014
|
0.89
|
|
19
|
Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review.
|
2012
|
0.87
|
|
20
|
Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?
|
2010
|
0.86
|
|
21
|
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.
|
2010
|
0.86
|
|
22
|
CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer.
|
2012
|
0.85
|
|
23
|
Escherichia coli Isolated from Urinary Tract Infections of Lebanese Patients between 2000 and 2009: Epidemiology and Profiles of Resistance.
|
2011
|
0.84
|
|
24
|
Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.
|
2011
|
0.83
|
|
25
|
A regimen of taxol, Ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal.
|
2011
|
0.83
|
|
26
|
Neoadjuvant treatment in rectal cancer: actual status.
|
2011
|
0.82
|
|
27
|
Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy.
|
2012
|
0.82
|
|
28
|
Neoadjuvant chemoradiation in squamous cell carcinoma of the maxillary sinus: a 26-year experience.
|
2012
|
0.82
|
|
29
|
Activity of Antimicrobial Peptides and Conventional Antibiotics against Superantigen Positive Staphylococcus aureus Isolated from the Patients with Neoplastic and Inflammatory Erythrodermia.
|
2011
|
0.82
|
|
30
|
Inhibition of NF- κ B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ -Radiation Cytotoxicity in Glioblastoma Cells.
|
2013
|
0.81
|
|
31
|
Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations.
|
2011
|
0.81
|
|
32
|
Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.
|
2012
|
0.81
|
|
33
|
Bevacizumab improves quality of life in patients with recurrent glioblastoma.
|
2011
|
0.80
|
|
34
|
Factors affecting the cost effectiveness of antibiotics.
|
2011
|
0.80
|
|
35
|
Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.
|
2011
|
0.79
|
|
36
|
Preparation and In Vivo Evaluation of Dichloro(1,2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer Micelles.
|
2012
|
0.79
|
|
37
|
Identification of Functional Regulatory Residues of the β -Lactam Inducible Penicillin Binding Protein in Methicillin-Resistant Staphylococcus aureus.
|
2013
|
0.79
|
|
38
|
Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.
|
2011
|
0.79
|
|
39
|
The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.
|
2016
|
0.79
|
|
40
|
Susceptibility of bifidobacteria of animal origin to selected antimicrobial agents.
|
2011
|
0.78
|
|
41
|
Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
|
2012
|
0.78
|
|
42
|
Induction chemotherapy in locally advanced pharyngolaryngeal cancers with stridor: is it feasible and safe?
|
2012
|
0.78
|
|
43
|
Cisplatin tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.
|
2011
|
0.78
|
|
44
|
Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.
|
2011
|
0.78
|
|
45
|
Carbapenem Resistance among Enterobacter Species in a Tertiary Care Hospital in Central India.
|
2014
|
0.78
|
|
46
|
EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.
|
2012
|
0.78
|
|
47
|
From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions.
|
2010
|
0.78
|
|
48
|
Developing central nervous system and vulnerability to platinum compounds.
|
2011
|
0.78
|
|
49
|
Lipoplatin treatment in lung and breast cancer.
|
2010
|
0.77
|
|
50
|
Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours.
|
2012
|
0.77
|